NMN or NR: which one has the evidence?
Two NAD+ precursors, each with named champions, marketed as rivals. Our records grade both, and the grades are the story: NMN at C+ evidence and C- worth it, NR at B- evidence and C worth it, both $30 to $60 a month. NR's higher evidence grade reflects how much is known about it, not better outcomes.
The two cases
The NMN case
NMN reliably raises blood NAD+ in human trials, roughly doubling it at 1,000 mg a day in a January 2026 trial, with elevation sustained in a 24-week University of Tokyo trial in older adults. One emerging functional signal: muscle insulin sensitivity improved 25 percent in overweight prediabetic postmenopausal women, unreplicated. Against it: the Tokyo trial found no effect on hearing (its primary outcome), physical function, or other outcomes despite the NAD+ rise, and a 2026 meta-analysis of 15 trials found no broad metabolic benefits.
The NR case
NR reliably raises blood NAD+ by roughly 50 to over 140 percent across multiple trials. Against it stands the biggest trial in this debate: NOPARK (JAMA 2026, 410 people with Parkinson's, one year) found no clinical benefit, with the NR group scoring slightly worse than placebo. The largest, longest test of an NAD+ precursor on a clinical endpoint was null.
Where each side overclaims
Both camps convert "raises NAD+" into aging claims. NAD+ elevation is a blood measurement, not a longevity outcome, and neither compound has a positive human trial on a hard health outcome. The NMN camp leans additionally on mouse data; the NR camp leans on trial count while its flagship trial is null.
Our graded bottom line
The rivalry is commercial. The evidence difference is about how much is known: NR has more human data and the bigger null; NMN has thinner data and no big test yet. Neither has earned an outcome claim, and our grades say exactly that, in that order.
The consensus meter
The meter is set after the first round of sourced positions is reviewed. Positions below are being compiled now.
What the experts say
Quoted directly, linked to the source. We never publish a position we have not verified.
- Expert positions are being sourced and verified. Check back with the weekly brief.
Related supplements
Last updated 2026-10-23. Educational information, not medical advice.